GENCODE

The Worldwide Nucleic Acid Sample Preparation Industry is Projected to Reach $11.2 Billion by 2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 7, 2023
Biotechnology, Genetics, Health, Stem Cells, DNA, CCDS, Long-string instrument, Agilent Technologies, Workflow, QIAGEN, GENCODE, NGS, TERT, Face, Exon, Chemistry, HMW, RefSeq, OGM, UHMW, Fine chemical, Vaccine, Tecan

and Bionano Genomics created a Long String VANTAGE, a brand-new DNA extraction automation product.

Key Points: 
  • and Bionano Genomics created a Long String VANTAGE, a brand-new DNA extraction automation product.
  • Ultra-high molecular weight (UHMW) DNA can be extracted with the instrument and used for optical genome mapping (OGM).
  • As a requirement for the sample preparation workflow at Bionano Genomics, high-quality and quantity UHMW DNA extraction is required.
  • The following are the demand drivers for the global nucleic acid sample preparation market:
    The market is expected to face some limitations due to the following challenges:

Insights on the Nucleic Acid Sample Preparation Global Market to 2032 - Increasing Use of Nucleic Acid Molecules in Various Therapeutic Areas Fuels Growth

Retrieved on: 
Wednesday, February 8, 2023
DNA, CCDS, Long-string instrument, Agilent Technologies, Workflow, QIAGEN, GENCODE, NGS, TERT, Face, Research, Exon, Chemistry, HMW, RefSeq, OGM, UHMW, Fine chemical, Tecan

In 2021, the North America nucleic acid sample preparation market dominated the global market with a 46.99% market share, and it is expected to hold its dominance throughout the forecast period 2022-2032.

Key Points: 
  • In 2021, the North America nucleic acid sample preparation market dominated the global market with a 46.99% market share, and it is expected to hold its dominance throughout the forecast period 2022-2032.
  • However, the Asia-Pacific (APAC) region, constituting several emerging economies, is expected to register the highest CAGR of 12.01% during the forecast period 2022-2032.
  • As a requirement for the sample preparation workflow at Bionano Genomics, high-quality and quantity UHMW DNA extraction is required.
  • Increased demand for high-quality reagents, kits, and related items has resulted from advancements in the nucleic acid sample preparation procedure.

Twist Bioscience Launches Exome 2.0 for Genomics Research

Retrieved on: 
Wednesday, October 20, 2021
Technology, Medical Devices, Genetics, Nanotechnology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Lists of diseases, Twist, Silicon, Doctor of Philosophy, Gene, Diagnosis, NASDAQ, CCDS, Genome, Genetics, Degenerative disease, GENCODE, Multimedia, Genomics, Catholic University of Leuven (1834–1968), Inherited disorders of trafficking, CEO, Human, Twist Bioscience, Workflow, ClinVar, RefSeq, Exome, Martek Biosciences Corporation, Fine chemical, Vaccine, Twist Exome 2.0, Twist Bioscience Corporation, TWIST EXOME 2.0, TWIST BIOSCIENCE CORPORATION

Twist continues to expand our portfolio of high-quality, best-in-class life science tools, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

Key Points: 
  • Twist continues to expand our portfolio of high-quality, best-in-class life science tools, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • With the launch of Exome 2.0, we now offer a complete portfolio of flexible, comprehensive exome options to support genomics researchers looking to identify the underpinnings of disease.
  • The Twist Exome 2.0 is an exome panel designed with thoughtfully curated content that includes comprehensive coverage of genes responsible for rare diseases, inherited disorders, and germline cancers in humans.
  • Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.

Agilent Announces New SureSelect Human All Exon V8

Retrieved on: 
Wednesday, June 2, 2021
Oncology, Health, Technology, Genetics, Software, Biotechnology, Branches of biology, Biology, DNA, Molecular biology, Genomics, Human genetics, Wellcome Trust, Exome sequencing, Exome, Human genome, Exon, GENCODE

Agilent Technologies Inc. (NYSE: A) today announced the release of SureSelect Human All Exon V8 a new exome design that provides comprehensive content and up-to-date coverage of protein coding regions from RefSeq, CCDS, and GENCODE.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced the release of SureSelect Human All Exon V8 a new exome design that provides comprehensive content and up-to-date coverage of protein coding regions from RefSeq, CCDS, and GENCODE.
  • The new design is available in three options routine exome sequencing (Exome v8), clinical research sequencing (v8 Clinical Plus), and translational research (v8 UTR Plus) allowing for content flexibility to meet our customers needs.
  • Powered by machine learning-based probe design and an improved probe-printing process, the SureSelect Human All Exon V8 spans a 35.1 Mb target region of the human genome, with an efficient end-to-end design size of only 41.6 Mb.
  • "The SureSelect Human All Exon V8 provides best-in-class enrichment performance and sequencing efficiency, and it shows our commitment to exceed customer expectations and continue our legacy as the benchmark exome to the genomics community."